Tag archive
Switching sterile API suppliers in pharma brings underestimated delays. Sterility validation and audits sharply raise timeline and operational risk.
Ranitidine recalls drive deeper shifts than forced substation—rerouting demand, distorting sourcing assumptions, and reshaping buyer-supplier strategies.
A crowded rare disease drug pipeline limits new drug differentiation, pushing biotechs and investors to re-assess risk, value creation, and portfolio strategy.
Akums Drugs' IPO debut with a 6.7% premium signals strong investor interest in pharma, reflecting broader sector trends.
What are natural pigments for pharmaceuticals, and why are formulators choosing them over...
Biocon's UK MHRA approval for its Malaysia unit signals a significant step in expanding its global insulin production capabilities.
Wockhardt's shares have surged. Dive into recent performance and assess if this momentum signals a promising investment.
Abiozen offers comprehensive pharmaceutical, biotechnology, and scientific services designed to...
What Happened Strides Pharma Science Limited, a prominent global pharmaceutical company,...
Hypertensive Heart Disease Market was valued at $150.8 billion in 2024 and is projected to reach...
Explore Granules India's 23% YoY revenue growth and future prospects in pharma. A deep dive into financial and technical insights.
Analyze Torrent Pharmaceuticals' stock surge to a 52-week high, exploring strategic decisions and market influences driving this growth.